Nano-Enabled Therapeutics: Novel Strategies for Preeclampsia Treatment

Yimin Huang,1 Xiaojuan Zhang,2 Lili Xue,3 Chuanchuan He1 1Department of Central Laboratory, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China; 2Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China; 3Department of Obstetrics, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of ChinaCorrespondence: Lili Xue, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China, Email beibeixuelili@163.com Chuanchuan He, Jiaxing Maternity and Child Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, People’s Republic of China, Email hechuanchuan@zjxu.edu.cnAbstract: Preeclampsia (PE), a pregnancy-specific disorder characterized by hypertension and placental dysfunction, remains a leading cause of maternal and fetal morbidities worldwide. Recent advances in nanomedicine offer promising therapeutic strategies by targeting placental pathologies. Studies have demonstrated that in PE mouse models, the regulation of key disease-related genes (such as sFlt1 and VEGF) using siRNA- or mRNA-loaded carriers (eg, lipid nanoparticles, exosomes, or elastin-like polypeptides) can effectively alleviate PE symptoms. This review summarizes the progress in nanoparticle-based therapies for PE, discusses challenges such as scalability and clinical translation, and highlights the potential of nanomedicine to revolutionize PE management.Keywords: preeclampsia, nanocarrier, placenta, sFlt1